For the CY 2026 OPPS/ASC proposed rule, we estimated that proposed pass-through spending for drugs, biologicals, and devices for CY 2026 will equal approximately $587 million, which represents 0.59 percent of total projected CY 2026 OPPS spending
Recent research from the National Institutes of Health (NIH) has highlighted that while GLP-1 medications are effective for weight management and blood sugar control, understanding their impact on nutrient absorption is crucial [1]
When paired with cycling or other moderate workouts, GLP-1s not only enhance fat loss but also build stamina, confidence, and resilience
1996;313 (Pt 1):1729
If more severe side effects occur, such as low blood sugar, contact your doctor immediately
Phase 3 trials are ongoing under the NCT registry (the TRIUMPH series, plus dedicated cardiovascular and kidney outcome trials NCT06383390, NCT05929066, NCT05931367, and NCT05882045)